Pharmacokinetics and Pharmacodynamics of Rivaroxaban – An Oral, Direct Factor Xa Inhibitor

E-ISSN： 2212-3938|9|1|75-83

ISSN： 1574-8847

Source： Current Clinical Pharmacology, Vol.9, Iss.1, 2014-02, pp. : 75-83

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Population Pharmacokinetics and Pharmacodynamics of Rivaroxaban - an Oral, Direct Factor Xa Inhibitor - in Patients Undergoing Major Orthopaedic Surgery

By Mueck Wolfgang

Clinical Pharmacokinetics, Vol. 47, Iss. 3, 2008-01 ,pp. : 203-216

Adis International

Access to resources Recommend Favorite

Rivaroxaban, the first oral, direct factor Xa inhibitor

By Fassiadis Nicholas

Expert Opinion on Pharmacotherapy, Vol. 10, Iss. 18, 2009-12 ,pp. : 2945-2946

Informa Healthcare

Access to resources Recommend Favorite

Rivaroxaban, an oral direct factor Xa inhibitor

By Piccini Jonathan P Patel Manesh R Mahaffey Kenneth W Fox Keith AA Califf Robert M

Expert Opinion on Investigational Drugs, Vol. 17, Iss. 6, 2008-06 ,pp. : 925-937

Informa Healthcare

Access to resources Recommend Favorite

Clinical Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Darexaban, an Oral Direct Factor Xa Inhibitor, in Healthy Elderly Japanese Subjects

Clinical Pharmacology In Drug Development, Vol. 2, Iss. 4, 2013-10 ,pp. : 328-335

John Wiley & Sons Inc

Access to resources Recommend Favorite

Comparative Pharmacodynamics and Pharmacokinetics of Oral Direct Thrombin and Factor Xa Inhibitors in Development

By Eriksson Bengt I.

Clinical Pharmacokinetics, Vol. 48, Iss. 1, 2009-01 ,pp. : 1-22

Adis International

Access to resources Recommend Favorite